Cargando…

Metabolic Tumor Volume Measured by (18)F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents

PURPOSE: The combination of PD-1/PD-L1 inhibitors and molecular targeted agents showed promising efficacy for unresectable hepatocellular carcinoma (uHCC). This study aimed to investigate the prognostic value of metabolic parameters from (18)F-fluorodeoxyglucose positron emission tomography-computed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xuezhu, Yang, Xu, Wang, Jingnan, Dong, Chengyan, Ding, Jie, Wu, Meiqi, Wang, Yanyu, Ding, Haiyan, Zhang, Hui, Sang, Xinting, Zhao, Haitao, Huo, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094465/ https://www.ncbi.nlm.nih.gov/pubmed/37063093 http://dx.doi.org/10.2147/JHC.S401647

Ejemplares similares

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
por: Yang, Xu, et al.
Publicado: (2023)

Dynamic (18)F-FDG PET imaging of liver lesions: evaluation of a two-tissue compartment model with dual blood input function
por: Wang, Jingnan, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
por: Wang, Jinfeng, et al.
Publicado: (2023)

The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
por: Wang, Guanyun, et al.
Publicado: (2023)

Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
por: Wang, Guanyun, et al.
Publicado: (2023)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World
por: Li, Xiaowei, et al.
Publicado: (2022)

Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
por: Mao, Jinzhu, et al.
Publicado: (2021)

Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
por: Chang, Xiujuan, et al.
Publicado: (2023)

PD-L1 in Lung Adenocarcinoma: Insights into the Role of (18)F-FDG PET/CT
por: Cui, Yan, et al.
Publicado: (2020)

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
por: Flaus, A., et al.
Publicado: (2021)

Prognostic significance of volume-based (18)F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma
por: Wang, Dalong, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
por: Huang, Jia-Xin, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
por: Yu, Bingran, et al.
Publicado: (2023)

Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients
por: Wei, Jia, et al.
Publicado: (2021)

Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
por: Jia, Meng, et al.
Publicado: (2022)

Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
por: Zhu, Chengpei, et al.
Publicado: (2023)

Identification of TMB, CD8 T‐cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit–toxicity ratio of anti‐PD‐1/PD‐L1 therapy
por: Long, Junyu, et al.
Publicado: (2021)

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
por: Li, Xingzhi, et al.
Publicado: (2023)

Prognostic significance of PD-L1 expression and (18)F-FDG PET/CT in surgical pulmonary squamous cell carcinoma
por: Zhang, Minghui, et al.
Publicado: (2017)

Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study
por: Chen, Song, et al.
Publicado: (2021)

Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Wu, Jia-Yi, et al.
Publicado: (2021)

Relationship between standardized uptake value on 18F-FDG PET and PD-L1 expression in clear cell renal cell carcinoma
por: Liu, Ying, et al.
Publicado: (2022)

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
por: Chen, Jiming, et al.
Publicado: (2022)

The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma
por: Zeng, Hui, et al.
Publicado: (2023)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

Role of the PD-1 and PD-L1 axis in COVID-19
por: R Bonam, Srinivasa, et al.
Publicado: (2022)

Comparative [18F]FDG and [18F]DPA714 PET imaging and time-dependent changes of brown adipose tissue in tumor-bearing mice
por: Niu, Na, et al.
Publicado: (2020)

Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma
por: Zhang, Ze, et al.
Publicado: (2023)

Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
por: Liu, Qingyan, et al.
Publicado: (2023)

(18)F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer
por: Borm, Frank Johannes, et al.
Publicado: (2020)

(18)F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab
por: Seban, Romain-David, et al.
Publicado: (2021)

Imaging PD-L1 Expression with ImmunoPET
por: Truillet, Charles, et al.
Publicado: (2017)

PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a (177)Lu-labeled αPD-L1 antibody
por: Ren, Jingyun, et al.
Publicado: (2021)

Retrospective Analysis of the Predictive Value of (18)F-FDG PET/CT Metabolic Parameters for PD-L1 Expression in Cervical Cancer
por: Ji, Jianfeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kher10q03c9m98l6uf9511bs40